Integrated Biopharma (INBP) Stock Price

Integrated Biopharma Price

OTC·CLOSED
0.16USD+0.00 (+0.00 %)
Market closed

Revenue at Integrated Biopharma has contracted by 0.3% per year over the past 19 years to 54.35 M USD. For Integrated Biopharma, the net margin of 1.5% is down versus 12.6% a few years ago. The stock trades about 7% above its 52-week low.

Integrated Biopharma stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Integrated Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Integrated Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Integrated Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Integrated Biopharma Stock Price History
DateIntegrated Biopharma Price
7/23/20260.16 USD
7/22/20260.16 USD
7/21/20260.16 USD
7/20/20260.16 USD
7/17/20260.16 USD
7/16/20260.17 USD
7/15/20260.16 USD
7/14/20260.16 USD
7/13/20260.16 USD
7/10/20260.16 USD
7/9/20260.16 USD
7/8/20260.16 USD
7/7/20260.17 USD
7/6/20260.15 USD
7/2/20260.18 USD
7/1/20260.18 USD
6/30/20260.18 USD
6/29/20260.18 USD
6/26/20260.18 USD
6/25/20260.18 USD
6/24/20260.17 USD
6/23/20260.18 USD
6/22/20260.18 USD
6/18/20260.19 USD
6/17/20260.19 USD
6/16/20260.19 USD
6/15/20260.19 USD
6/12/20260.18 USD
6/11/20260.18 USD
6/10/20260.18 USD
6/9/20260.18 USD
6/8/20260.18 USD
6/5/20260.18 USD
6/4/20260.18 USD
6/3/20260.19 USD
6/2/20260.19 USD
6/1/20260.19 USD
5/29/20260.18 USD
5/28/20260.18 USD
5/27/20260.18 USD
5/26/20260.18 USD
5/22/20260.19 USD
5/21/20260.19 USD
5/20/20260.18 USD
5/19/20260.22 USD
5/18/20260.20 USD
5/15/20260.21 USD
5/14/20260.22 USD
5/13/20260.21 USD
5/12/20260.25 USD
5/11/20260.25 USD
5/8/20260.25 USD
5/7/20260.25 USD
5/6/20260.25 USD
5/5/20260.25 USD
5/4/20260.25 USD
5/3/20260.25 USD
4/15/20260.28 USD
4/13/20260.28 USD
4/10/20260.26 USD
4/9/20260.27 USD
4/7/20260.29 USD
4/6/20260.29 USD
4/1/20260.28 USD
3/31/20260.27 USD
3/27/20260.29 USD
3/26/20260.28 USD
3/23/20260.30 USD
3/20/20260.29 USD
3/19/20260.29 USD
3/17/20260.28 USD
3/16/20260.29 USD
3/13/20260.30 USD
3/12/20260.30 USD
3/11/20260.30 USD
3/2/20260.30 USD
2/25/20260.29 USD
2/24/20260.30 USD
2/23/20260.30 USD
2/19/20260.30 USD
2/17/20260.30 USD
2/16/20260.30 USD
2/13/20260.30 USD
2/11/20260.31 USD
2/9/20260.32 USD
2/6/20260.34 USD
2/5/20260.33 USD
2/2/20260.34 USD
1/30/20260.33 USD
1/29/20260.32 USD
1/28/20260.34 USD
1/27/20260.34 USD
1/26/20260.34 USD
1/23/20260.36 USD
1/21/20260.36 USD
1/20/20260.35 USD
1/15/20260.37 USD
1/13/20260.37 USD
1/12/20260.35 USD
1/9/20260.35 USD
1/7/20260.34 USD
1/6/20260.37 USD
1/5/20260.38 USD
1/2/20260.37 USD
12/31/20250.36 USD
12/30/20250.32 USD
12/29/20250.34 USD
12/26/20250.31 USD
12/24/20250.31 USD
12/23/20250.31 USD
12/22/20250.31 USD
12/19/20250.31 USD
12/18/20250.31 USD
12/16/20250.29 USD
12/15/20250.31 USD
12/12/20250.29 USD
12/11/20250.31 USD
12/9/20250.31 USD
12/8/20250.31 USD
12/7/20250.31 USD
12/3/20250.31 USD
12/2/20250.30 USD
12/1/20250.31 USD
11/27/20250.32 USD
11/26/20250.32 USD
11/24/20250.32 USD
11/23/20250.32 USD
11/21/20250.32 USD
11/19/20250.31 USD
11/18/20250.31 USD
11/17/20250.30 USD
11/16/20250.31 USD
11/13/20250.27 USD
11/12/20250.29 USD
11/11/20250.29 USD
11/10/20250.29 USD
11/9/20250.31 USD
11/7/20250.31 USD
11/5/20250.29 USD
11/4/20250.29 USD
11/2/20250.30 USD
10/30/20250.31 USD
10/28/20250.30 USD
10/27/20250.31 USD
10/24/20250.31 USD
10/22/20250.30 USD
10/21/20250.30 USD
10/15/20250.31 USD
10/13/20250.31 USD
10/12/20250.31 USD
10/9/20250.31 USD
10/6/20250.31 USD
10/3/20250.28 USD
10/2/20250.28 USD
10/1/20250.29 USD
9/30/20250.29 USD
9/29/20250.29 USD
9/25/20250.30 USD
9/24/20250.31 USD
9/23/20250.32 USD
9/22/20250.33 USD
9/18/20250.28 USD
9/16/20250.29 USD
9/15/20250.29 USD
9/12/20250.29 USD
9/11/20250.29 USD
9/9/20250.28 USD
9/8/20250.27 USD
9/4/20250.27 USD
9/3/20250.27 USD
9/1/20250.27 USD
8/29/20250.26 USD
8/28/20250.27 USD
8/25/20250.27 USD
8/19/20250.26 USD
8/18/20250.26 USD
8/13/20250.27 USD
8/12/20250.30 USD
8/6/20250.28 USD
8/5/20250.28 USD
8/4/20250.28 USD
7/31/20250.28 USD
7/29/20250.29 USD
7/28/20250.29 USD
7/27/20250.29 USD
Access this data via the Eulerpool API

Integrated Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
43.71 M USD
1.69 M USD
679,000.00 USD
Jan 1, 2019
49.98 M USD
2.70 M USD
1.69 M USD
Jan 1, 2020
52.77 M USD
3.26 M USD
4.11 M USD
Jan 1, 2021
63.56 M USD
5.78 M USD
8.01 M USD
Jan 1, 2022
56.25 M USD
2.75 M USD
3.84 M USD
Jan 1, 2023
50.67 M USD
120,000.00 USD
-34,000.00 USD
Jan 1, 2024
50.32 M USD
251,000.00 USD
112,000.00 USD
Jan 1, 2025
54.35 M USD
2.02 M USD
808,000.00 USD

Integrated Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 25, 2026, 6:45 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
37.0025.0036.0033.0033.0037.0042.0046.0043.0049.0052.0063.0056.0050.0050.0054.00
-5.13-32.4344.00-8.3312.1213.519.52-6.5213.956.1221.15-11.11-10.718.00
21.6216.0022.2215.1512.1210.8111.9013.049.3012.2411.5414.2912.508.006.009.26
8.004.008.005.004.004.005.006.004.006.006.009.007.004.003.005.00
1.001.002.003.001.002.003.005.002.002.00
3.033.034.766.522.334.085.777.943.573.70
2.001.004.008.003.00
300.00100.00-62.50
5.185.185.185.185.185.185.185.185.185.185.185.185.185.185.185.18
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Integrated Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Integrated Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Integrated Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Integrated Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Integrated Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Integrated Biopharma stock margins

The Integrated Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integrated Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integrated Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
11.41 %
3.88 %
1.55 %
Jan 1, 2019
12.45 %
5.41 %
3.38 %
Jan 1, 2020
12.75 %
6.18 %
7.78 %
Jan 1, 2021
14.92 %
9.10 %
12.61 %
Jan 1, 2022
13.13 %
4.88 %
6.82 %
Jan 1, 2023
8.01 %
0.24 %
-0.07 %
Jan 1, 2024
7.72 %
0.50 %
0.22 %
Jan 1, 2025
10.23 %
3.72 %
1.49 %

Integrated Biopharma Stock Revenue, EBIT, Earnings per Share

The Integrated Biopharma earnings per share therefore indicates how much revenue Integrated Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Integrated Biopharma business model & stock analysis

Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry.

Integrated Biopharma SWOT Analysis

Strengths

Integrated Biopharma Inc has a strong portfolio of biopharmaceutical products, including a diverse range of nutritional supplements and vitamins. These products are highly regarded for their quality and effectiveness.

The company has a well-established distribution network, allowing it to reach a wide customer base and expand its market share. This gives Integrated Biopharma Inc a competitive advantage over smaller companies in the industry.

Integrated Biopharma Inc is known for its research and development capabilities, constantly innovating and introducing new products to meet the evolving needs of consumers. This positions the company as a leader in the biopharmaceutical sector.

Weaknesses

One of the weaknesses of Integrated Biopharma Inc is its dependence on external suppliers for raw materials. Any disruption in the supply chain could impact the company's production capacity and product availability.

The company has limited market presence in certain geographical regions, limiting its access to potential customers. This poses a challenge for expanding its global reach and market penetration.

Integrated Biopharma Inc faces increasing competition from both established pharmaceutical companies and emerging biotech startups. This heightens the pressure to continuously innovate and differentiate its products to maintain a competitive edge.

Opportunities

The growing trend towards natural and organic products presents an opportunity for Integrated Biopharma Inc to further capitalize on its existing product line of nutritional supplements and vitamins.

Expanding into new markets, particularly in emerging economies, can open up new revenue streams for Integrated Biopharma Inc. These markets often have a rising middle class with increasing purchasing power and demand for healthcare products.

The advancements in biotechnology and personalized medicine offer potential for Integrated Biopharma Inc to develop innovative products that cater to specific patient needs. This can enhance the company's market position and profitability.

Threats

Changing government regulations and policies related to healthcare and pharmaceutical products pose a significant threat to Integrated Biopharma Inc. Compliance with these regulations can be costly and time-consuming.

The risk of intellectual property infringement and the emergence of generic products can erode Integrated Biopharma Inc's market share and profitability. Protecting its intellectual property rights through patents and trademarks is crucial.

Economic downturns and fluctuations in exchange rates can impact consumer spending patterns and affect the demand for healthcare products, potentially impacting Integrated Biopharma Inc's sales and revenue.

Integrated Biopharma Segments

Integrated Biopharma Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Contract Manufacturing
Other Nutraceutical Business
Branded Proprietary Products
Details
Date
Contract Manufacturing
Other Nutraceutical Business
Branded Proprietary Products
Jan 1, 2013
29.31 M USD
2.03 M USD
2.28 M USD
Jan 1, 2018
0.00 USD
1.38 M USD
252,000.00 USD
Jan 1, 2019
48.44 M USD
1.38 M USD
159,000.00 USD
Jan 1, 2020
51.33 M USD
1.44 M USD
0.00 USD

Integrated Biopharma Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • Max

Contract Manufacturing
Details
Date
Contract Manufacturing
Jan 1, 2013
0.00 USD
Jan 1, 2018
42.08 M USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD

Integrated Biopharma Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
US Customers
International
Europe and Canada
Other Countries
International Customers
Details
Date
United States
US Customers
International
Europe and Canada
Other Countries
International Customers
Jan 1, 2013
0.00 USD
20.83 M USD
12.80 M USD
0.00 USD
0.00 USD
12.80 M USD
Jan 1, 2018
37.24 M USD
0.00 USD
0.00 USD
6.47 M USD
0.00 USD
6.47 M USD
Jan 1, 2019
137,000.00 USD
0.00 USD
0.00 USD
6.81 M USD
22,000.00 USD
0.00 USD
Jan 1, 2020
42.94 M USD
0.00 USD
0.00 USD
8.47 M USD
8.38 M USD
0.00 USD

Integrated Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Integrated Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Integrated Biopharma annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Integrated Biopharma shares outstanding

The number of shares of Integrated Biopharma was 31.17 M in 2025. This indicates how many shares Integrated Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
31.17 M Stocks
Jan 1, 2019
31.17 M Stocks
Jan 1, 2020
31.17 M Stocks
Jan 1, 2021
31.17 M Stocks
Jan 1, 2022
31.17 M Stocks
Jan 1, 2023
31.17 M Stocks
Jan 1, 2024
31.17 M Stocks
Jan 1, 2025
31.17 M Stocks
Price targets and forecasts for Integrated Biopharma are not yet available.

Integrated Biopharma shareholder structure

% Name
33.76552%
CD Financial, L.L.C.
CD Financial, L.L.C.
10.88864%
E Gerald Kay UEO
E Gerald Kay UEO
7.19578%
Carl DeSantis Revocable Trust
Carl DeSantis Revocable Trust
5.21472%
Kay (Heidi)
Kay (Heidi)
5.06976%
Kay (Christina)
Kay (Christina)
4.83138%
Sheppard (Riva Kay)
Sheppard (Riva Kay)

Integrated Biopharma Executives and Management Board

DM

Ms. Dina Masi

(63)

Chief Financial Officer, Senior Vice President, Secretary

Compensation357,081.00 USD
CK

Ms. Christina Kay

(54)

Co-Chief Executive Officer, Director · since 1994

Compensation343,553.00 USD
RS

Mrs. Riva Sheppard

(57)

Co-Chief Executive Officer, Director · since 1991

Compensation343,553.00 USD
WM

Mr. William Milmoe

(76)

Director

Compensation23,795.00 USD
RC

Mr. Robert Canarick

(74)

Independent Director

Compensation23,795.00 USD

Frequently asked questions about Integrated Biopharma

Integrated Biopharma Inc is a leading biopharmaceutical company that specializes in the development, manufacturing, and distribution of innovative healthcare products. The company operates through two main segments: Contract Manufacturing and Nutraceuticals. Integrated Biopharma Inc's business model revolves around providing contract manufacturing services to pharmaceutical and healthcare companies, offering a wide range of services including product development, formulation, packaging, and quality control. Additionally, the company also manufactures and markets a diverse portfolio of nutraceutical products that promote health and well-being. Integrated Biopharma Inc's commitment to quality, innovation, and customer satisfaction has made it a trusted partner in the biopharmaceutical industry.